Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector
Reexamination Certificate
2007-01-09
2007-01-09
Ungar, Susan (Department: 1642)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Reexamination Certificate
active
11208541
ABSTRACT:
A cancer antigen peptide comprising an amino acid sequence shown in SEQ ID NO: 1 or 2, or a derivative thereof having the functionally equivalent property is provided. The provided cancer antigen peptide is a partial peptide derived from enhancer of zeste homolog 2, which is capable of binding to HLA-A24 antigen and is recognized by cytotoxic T lymphocytes. The cancer antigen peptide of the invention is useful for treatment and prevention of prostate cancer.
REFERENCES:
patent: 5925388 (1999-07-01), Moineau et al.
patent: 6689583 (2004-02-01), Jenuwein et al.
Bowie et al (Science, 1990, 257:1306-1310).
Burgess et al (J of Cell Biol. 111:2129-2138, 1990).
Lazar et al (Molecular and Cellular Biology, 1988, 8:1247-1252).
R. T. Greenlee et al., “Cancer Statistics, 2000”, CA Cancer J. Clin., vol. 50, No. 1, pp. 7-33, Jan./Feb. 2000.
M. Harada et al., “Target molecules in specific immunotherapy against prostate cancer”, Intl. J. Clinical Oncology, vol. 8, pp. 193-199, 2003.
J. Gulley et al., “Phase I Study of a Vaccine using Recombinant Vaccinia Virus Expressing PSA (rV-PSA) in Patients with Metastatic Androgen-Independent Prostate Cancer”, The Prostate, vol. 53, pp. 109-117, 2002.
G. Murphy et al., “Phase I Clinical Trial: T-Cell Therapy for Prostate Cancer using Autologous Dendritic Cells Pulsed with HLA-A0201-Specific Peptides from Prostate-Specific Membrane Antigen”, The Prostate, vol. 29, pp. 371-380, 1996.
B. A. Tjoa et al., “Evaluation of Phase I/II Clinical Trials in Prostate Cancer with Dendritic Cells and PSMA Peptides”, The Prostate, vol. 36, pp. 39-44, 1998.
G. P. Murphy et al., “Infusion of Dendritic Cells Pulsed with HLA-A2-Specific Prostate-Specific Membrane Antigen Peptides: A Phase II Prostate Cancer Vaccine Trial Involving Patients with Hormone-Refractory Metastatic Disease”, The Prostate, vol. 38, pp. 73-78, 1999.
E. J. Small et al., “Immunotherapy of Hormone-Refractory Prostate Cancer with Antigen-Loaded Dendritic Cells” Journal of Clinical Oncology, vol. 18, No. 23, pp. 3894-3903, Dec. 1, 2000.
G. Laible et al., “Mammalian homologues of the Polycomb-group gene Enhancer of zeste mediate gene silencing inDrosophila heterochromatinand atS. cerevisiaetelomeres”, The EMBO Journal, vol. 16, No. 11, pp. 3219-3232, 1997.
C. G. Kleer et al., “EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells”, PNAS, vol. 100, No. 20, pp. 11606-11611, Sep. 30, 2003.
J. J. L. Jacobs et al., “The oncogene and polycomb-group genebmi-1 regulates cell proliferation and senescence through theink4a locus”, Letters to Nature, vol. 397, pp. 164-168, Jan. 1999.
J. J. L. Jacobs et al., “Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF”, Genes & Development, vol. 13, pp. 2678-2690, 1999.
S. Varambally et al., “The polycomb group protein EZH2 is involved in progression of prostate cancer”, Letters to Nature, vol. 419, pp. 624-629, Oct. 10, 2002.
M. Noguchi et al., “Induction of Cellular and Humoral Immune Responses to Tumor Cells and Peptides in HLA-A24 Positive Hormone-Refractory Prostate Cancer Patients by Peptide Vaccination”, The Prostate, vol. 57, pp. 80-92, 2003.
S. Tanaka et al., “Peptide Vaccination for Patients with Melanoma and other Types of Cancer based on Pre-existing Peptide-Specific Cytotoxic T-Lymphocyte Precursors in the Periphery”, Journal of Immunotherapy, vol. 26, No. 4, pp. 357-366, Jul./Aug. 2003.
T. Mine et al., “Immunological evaluation of CTL precursor-oriented vaccines for advanced lung cancer patients”, Cancer Science, vol. 94, No. 6, pp. 548-556, Jun. 2003.
Y. Sato et al., “Immunological evaluation of peptide vaccination for patients with gastric cancer based on pre-existing cellular response to peptide”, Cancer Science, vol. 94, No. 9, pp. 802-808, Sep. 2003.
N. Tsuda et al., “Vaccination with Predesignated or Evidence-Based Peptides for Patients with Recurrent Gynecologic Cancers”, J. Immunother, vol. 27, No. 1, pp. 60-72, Jan./Feb. 2004.
T. Nakatsura et al., “Cellular and humoral immune responses to a human pancreatic cancer antigen, coactosin-like protein, originally defined by the SEREX method”, Eur. J. Immunol., vol. 32, pp. 826-836, 2002.
K. C. Parker et al., “Scheme for Ranking Potential HLA-A2 Binding Peptides Based on Independent Binding of Individual Peptide Side-Chains”, J. Immunol., vol. 152, pp. 163-175, 1994.
S. Ohkouchi et al., “Non-mutated tumor-rejection antigen peptides elicit type-I allergy in the majority of healthy individuals”, Tissue Antigens, vol. 59, pp. 259-272, 2002.
N. Hida et al., “A simple culture protocol to detect peptide-specific cytotoxic T lymphocyte precursors in the circulation”, Cancer Immunol. Immunother, vol. 51, pp. 219-228, 2002.
N. Kawamoto et al., “IgG reactive to CTL-directed epitopes of self-antigens is either lacking or unbalanced in atopic dermatitis patients”, Tissue Antigens, vol. 61, pp. 352-361, 2003.
M. Harada et al., “Prostate-Specific Antigen-Derived Epitopes Capable of Inducing Cellular and Humoral Responses in HLA-A24+Prostate Cancer Patients”, The Prostate, vol. 57, pp. 152-159, 2003.
K. Kobayashi et al., “Identification of a prostate-specific membrane antigen-derived peptide capable of eliciting both cellular and humoral immune responses in HLA-A24+prostate cancer patients”, Cancer Science, vol. 94, No. 7, pp. 622-627, Jul. 2003.
S. Matsueda et al., “Identification of new prostate stem cell antigen-derived peptides immunogenic in HLA-A2+patients with hormone-refractory prostate cancer”, Cancer Immunol. Immunother, vol. 53, pp. 479-489, 2004.
Y. Inoue et al., “Induction of Tumor Specific Cytotoxic T Lymphocytes in Prostate Cancer using Prostatic Acid Phosphatase Derived HLA-A2402 Binding Peptide”, The Journal of Urology, vol. 166, pp. 1508-1513, Oct. 2001.
T. Imanishi et al., “Allele and haplotype frequencies for HLA and complement loci in various ethnic groups”, HLA 1991, vol. 1, Oxford: Oxford Scientific Publications, 1992, pp. 1065-1220.
M. Harada et al., “In Vivo Evidence that Peptide Vaccination can Induce HLA-DR-Restricted CD4+T Cells Reactive to a Class I Tumor Peptide”, The Journal of Immunology, vol. 172, pp. 2659-2667, 2004.
Harada Mamoru
Itoh Kyogo
Green Peptide Co., Ltd.
Joyce Catherine
Ungar Susan
Wenderoth , Lind & Ponack, L.L.P.
LandOfFree
HLA-A24 binding peptides of enhancer of zeste homolog 2 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with HLA-A24 binding peptides of enhancer of zeste homolog 2, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and HLA-A24 binding peptides of enhancer of zeste homolog 2 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3807342